64Cu-SAR-BBN

DRUG2 trials

Sponsors

Clarity Pharmaceuticals Ltd

Conditions

Biochemical Recurrence of Malignant Neoplasm of ProstateCastration-ResistantProstatic Neoplasms

Phase 1

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

TerminatedNCT05633160

Clarity Pharmaceuticals LtdCastration-Resistant, Prostatic Neoplasms

Start: 2023-06-15End: 2025-04-23Updated: 2025-08-29

Phase 2

64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

CompletedNCT05407311

Clarity Pharmaceuticals LtdBiochemical Recurrence of Malignant Neoplasm of Prostate

Start: 2022-09-19End: 2024-05-13Updated: 2025-11-17

Related Papers

COMBAT: A study of <sup>64</sup>Cu-SAR-BBN and <sup>67</sup>Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.

Journal of Clinical Oncology2024-01-292 citations

SABRE: Assessment of safety and efficacy of <sup>64</sup>Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.

Journal of Clinical Oncology2024-01-291 citations